Study (first author) | Country | Study design | Total sample size | Case | Control | Etiology of IC condition | Type of vaccine | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
No. of cases | Male, % of cases | Age | No. of non-cases (if applicable) | Male, % of non-cases | Age | ||||||
Sattler A | Germany | Prospective cohort | 78 | 39 | 71.8 | 57.3 | 39 | 51.2 | 53.0 | Transplant | BNT162b2 (Pfizer/BionTech) |
Rincon-Arevalo H | Germany | Prospective cohort | 75 | 40 | 70 | 62.4 [51.2–69.5]* | 35 | 57.1 | 51 [34–80]* | Transplant | BNT162b2 (Pfizer/BionTech) |
Korth J | Germany | Prospective cohort | 46 | 23 | 48 | 57.7 | 23 | 39 | 44.4 | Transplant | BNT162b2 (Pfizer/BionTech) |
Rabinowich L | Israel | Cross-sectional | 105 | 80 | 70 | 60.1 | 25 | 32 | 52.7 | Transplant | BNT162b2 (Pfizer/BionTech) |
Schramm R | Germany | Prospective cohort | 100 | 50 | 64 | 55 | 50 | 34 | 47 | Transplant | BNT162b2 (Pfizer/BionTech) |
Cao J | USA | Retrospective cohort | 47 | 37 | 72.9 | 64 [50–69]* | 10 | 20 | 66 [57–75]* | Transplant | mRNA-1273 (Moderna) or BNT162b2 (Pfizer/BionTech) |
Grupper A | Israel | Retrospective cohort | 151 | 136 | 81.7 | 58.6 | 25 | 32 | 52.7 | Transplant | BNT162b2 (Pfizer/BionTech) |
Marinaki S | Greece | Prospective cohort | 150 | 34 | 79.4 | 60 [49.1–68.4]* | 116 | – | – | Transplant | BNT162b2 (Pfizer/BionTech) |
Rashidi-Alavijeh J | Germany | Prospective cohort | 63 | 43 | 60.5 | 57 [49–64]* | 20 | 45 | 43.5 [38–53.5]* | Transplant | BNT162b2 (Pfizer/BionTech) |
Hod T | Israel | Prospective cohort | 322 | 120 | 80 | 59.7 | 141 | 30.2 | 57.04 | Transplant | BNT162b2 (Pfizer/BionTech) |
Stumpf J | Germany | Prospective cohort | 512 | 368 | 65.5 | 57.3 | 144 | 23.6 | 48 | Transplant | (a) mRNA-1273 (Moderna) (n = 143); (b) BNT162b2 (Pfizer/BionTech) (n = 369) |
Firket L | USA | Retrospective cohort | 40 | 20 | 45 | 51.2 | 20 | 65 | 48.3 | Transplant | BNT162b2 (Pfizer/BionTech) |
Peled Y | Israel | Prospective cohort | 213 | 77 | 64 | 62 [49–68]* | 136 | 37 | 63 | Transplant | BNT162b2 (Pfizer/BionTech) |
Monin L | UK | Prospective cohort | 205 | 151 | 52 | 73 [64.5–79.5]* | 54 | 52 | 40.5 [31.3–50]* | Malignancy | BNT162b2 (Pfizer/BionTech) |
Pimpinelli F | Italy | Prospective cohort | 128 | 92 | 53/2 | 70* | 36 | 0 | 81 | Malignancy | BNT162b2 (Pfizer/BionTech) |
Massarweh A | Israel | Prospective cohort | 180 | 102 | 57 | 66 [56–72]* | 78 | 32 | 62 [49–70]* | Malignancy | BNT162b2 (Pfizer/BionTech) |
Agbarya A | Israel | Cross-sectional | 355 | 140 | 54 | 65.3 | 215 | 37.2 | 62.5 | Malignancy | BNT162b2 (Pfizer/BionTech) |
Herishanu Y | Israel | Prospective cohort | 219 | 167 | 67.1 | 71 [63–76]* | 52 | – | 69 [63–73.7]* | Malignancy | BNT162b2 (Pfizer/BionTech) |
Iacono D | Italy | Cross-sectional | 108 | 36 | 41.6 | 82* | 72 | – |  ≥ 66 | Malignancy | BNT162b2 (Pfizer/BionTech) |
Malard F | France | Retrospective cohort | 225 | 195 | 60 | 68.9* | 30 | – | – | Malignancy | BNT162b2 (Pfizer/BionTech) |
Eliakim-Raz N | Israel | Prospective cohort | 161 | 95 | 58 | 65 [56–72]* | 66 | 32 | 62 [50–70]* | Malignancy | BNT162b2 (Pfizer/BionTech) |
Herzog Tzarfati K | Israel | Prospective cohort | 423 | 315 | 56 | 71 [61–78]* | 108 | 44 | 69 [58–74]* | Malignancy | BNT162b2 (Pfizer/BionTech) |
Reuken P | Germany | Prospective cohort | 55 | 28 | 46.4 | 42 [36–59]* | 27 | – | – | Autoimmune | BNT162b2 (Pfizer/BionTech) |
Geisen UM | Germany | Retrospective cohort | 68 | 42 | 35.7 | 50.5 | 26 | 30.8 | 37.5 | Autoimmune | mRNA-1273 (Moderna) or BNT162b2 (Pfizer/BionTech) |
Furer V | Israel | Prospective cohort | 807 | 686 | 30.7 | 59 [19–88]* | 121 | 35 | 50* | Autoimmune | BNT162b2 (Pfizer/BionTech) |
Prendecki M | UK | Prospective cohort | 155 | 85 | 52.1 | 52 [39.9–63.9]* | 70 | – | 41.4* | Autoimmune | BNT162b2 (Pfizer/BionTech) |